AA is projected to have 10% growth year over year... plus it is closing lower margin business and expanding higher margin business. Currently trades @ 10x forward earnings... as they continue to grow their specialty/value added materials business.
Either this is being manipulated or AA is deceiving shareholders.
The issue is not tolerating statins -- the issue is whether this drug works! And when data supporting it might be available. Where is the actual FDA report?
The Forbes article says " the FDA panel was pretty clear that it didn’t think that approving a drug for patients who can’t tolerate statins is a good idea, at least without hard proof that the drug can prevent heart attacks and strokes, as statins do. Nine of the sixteen panelists said that they were against a statin intolerant indication without such data."
Sounds pretty clear that they are talking about APPROVAL. Getting docs to prescribe is another issue altogether. FDA panel wants "hard proof" that this prevents heart attacks and strokes... and I am assuming this does not exist or this would not be an issue.
Anyone seen the panel's actual language?
Seems really irresponsible unless he has inside info at the FDA. Maybe he is just attempting to prop this up to give the people he recommended this to a chance to get out without a panic. This company is burning cash hand over fist, has no prospects for revenue in the next couple of years, and basically just had the future of their sole asset called into jeopardy. I don't get it.
Have followed this company for a while and watched it skyrocket. My question is, based on FDA advisory panel comments, and the fact that this drug has been in development for 12 years, why are there no trials showing efficacy? If this drug is worthless, ESPR is going to zero... if it works at lowering LDL cholesterol AND reducing heart attacks (safely), then it could go to the moon... but where is the data, and why is it not clear after 12 years? And why have other drug developers moved away from this line of development?
Anyone who buys or sells based on the Yahoo!Finance page data is in big trouble and not doing their due diligence
wish I was a millionaire... which I assume you are... either that or you are a gambler in need of an intervention. So you just dropped 80G in ONCS? Wow! And lost 6G in the first hours? Ever hear of diversification? Ever hear of dollar cost averaging? Not sure why I am responding to a post that I suspect is bogus... maybe it is because I am rethinking my long position in ONCS if this is the investing style of people buying in... This is a very speculative stock...
He is paid to be a professional CEO not a braying jacka##. As a long term MYL shareholder, I am appalled by his behavior. I believe he is damaging the company... not nec. sales, but goodwill and reputation
Important to like PRGO at this price as well... as that is what you will be holding if the MYL deal does not happen. And PRGO rejections of the deal, plus Teva's continued pursuit of MYL make this somewhat dicey. Also, if Teva bails on MYL, we could see a precipitous drop in MYL shares... which would not be good for PRGO shares... or the MYL offer. This is a high stakes poker game, and the outcome looks very uncertain. And who knows... an as yet unknown third party could step in and take out one of these companies.
Starting to get old? SWKS is up 130% in a year... down about 8% from its all time high of maybe 2 weeks ago? I'm guessing you jumped on the bandwagon at the high and are feeling burned. Nothing goes straight up... and there is a lot of pressure on chips. When analysts start upgrading after a big run, I feel like it is time to get out. Often it seems they are just propping up price for their big clients to get out.
Or will sell at $65. after all these deals fall through. Coury burned MYL shareholders through the Tax Inversion -- and will burn them again with his arrogant self-serving approach... either that or he is a better poker player (and CEO) than I am giving him credit for. I am holding and hoping for the best.
How much dilution does the the PRGO bring? Mylan's offer says PRGO offers a better value than Mylan's own shares. If MYL shares are worth $120. stand alone(as many posters claim)... then this values PRGO shares @ $351. a nearly 100% premium to todays price. At $100./MYL share, a PRGO share is worth $305. My concern is Coury is overpaying for PRGO to protect his personal interests... not shareholders... not stakeholders... and Mylan shareholders are overlooking the degree of dilution the PRGO deal brings. The desperation on Coury's part to avoid a Teva deal may prove worse for Mylan shareholders than a deal itself. I have been long MYL for over 5 years.
You believe there is overlap between WFM and WMT in the grocery segment? I shop at Whole Foods, Trader Joe's, our local farmer's market (which is probably bigger than WalMart), and in a pinch, Publix or Kroger's -- though I don't really feel comfortable with their fish or produce. I will also shop at WalMart occasionally... for dishwasher soap, school supplies, socks, batteries... even bought a bicycle there recently. But I NEVER buy there produce, or other food items. WFM is not competing with WMT for customers... and I don't really think they are competing with Publix or Kroger either. Some people place a priority for what they put in their body. They will pay more for organic chicken or Bell & Evans, but wouldn't buy Purdue or generic chicken. On the other hand, I really don't care what car I drive (a 1999 model). Food is more important to me.
Mylan basicly scr*#ed long-term shareholders with their inversion back in Feb. Made most of their gains taxable this year will force many shareholders out of the stock. I am still holding, but will have to sell before EOY to lock in gains and pay taxes. Might as well get highest value possible in the short term.
Unfortunately, Yahoo Finance has bad info... MYL cap is 35+ B... not 28
Someone please tell me what I am missing. Reports value the TEVA offer at 40+ billion. Current MYL market cap is 28B... 40 billion would seem to translate into an offer around $105. So somewhere the numbers being reported appear wrong. Insight appreciated. Thanks.
Oh come on... you know he covered at $66.37, and after shorting at 72.37 on 25k shares, made a cool hundred and fifty grand for a good weeks work
Sentiment: Strong Buy
Sales are expected to grow 20+% next year and this trades @ a sub 20 forward P/E... and all you do is bash without any substantive facts. "Old generics... fraud... dissected their pipeline... yada yada..." Obviously doctors are prescribing their products... or they would not be growing and profitable... I reached out to an analyst I know and he feels they have a good model of older/orphan drugs, R&D, and have even started manufacturing. They have a strategic approach that is working -- growing and high margin. Many still see them as a takeover candidate.